P787: SABATOLIMAB (MBG453) COMBINATION TREATMENT REGIMENS FOR PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES: THE MYELODYSPLASTIC SYNDROMES STUDIES IN THE STIMULUS IMMUNO-MYELOID CLINICAL TRIAL PROGRAM. (23rd June 2022) - Zeidan, A. M.; Al-Kali, A.; Borate, U.; Cluzeau, T.; DeZern, A. E.; Esteve, J.; Giagounidis, A.; Kobata, K.; Lyons, R.; Platzbecker, U.; Sallman, D. A.; Santini, V.; et al.